Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
Advances in Clinical Medicine · 2024 · 14 (03) · 374-381
DOI: 10.12677/acm.2024.143712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical Medicine, 2024. Verfasst von 立雪 张. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer is a specific type of breast cancer with a poor prognosis. Neoadjuvant chemotherapy combined with targeted therapy, i.e., neoadjuvant therapy, has become an important component in the comprehensive treatment of this type of breast cancer. Pathologic complete remission (pCR) has been recognized as an independent prognostic predictor for HER-2-positive breast cancer. During neoadjuvant therapy, some patients develop resistance to therapeutic agents, which can affect prognosis. Finding appropriate prognostic predictors and changing the optimal treatment regimen in time can greatly improve the prognosis of HER-2 positive breast cancer patients. This article describes the biomarkers associated with the prognosis of HER-2-positive breast cancer in the hope that they can provide reference for the selection of clinical treatment programs and improve the efficiency of treatment.
Zitieren
APA
张, 立. (2024). Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer. Advances in Clinical Medicine, 14(03), 374-381. https://doi.org/10.12677/acm.2024.143712
Vancouver
张 立. Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer. Advances in Clinical Medicine. 2024;14(03):374-381. doi:10.12677/acm.2024.143712
BibTeX
@article{2024,
author = {张, 立雪},
title = {Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer},
journal = {Advances in Clinical Medicine},
year = {2024},
volume = {14},
number = {03},
pages = {374--381},
doi = {10.12677/acm.2024.143712}
}
EUVIMED